Skip to main content

Acromegaly clinical trials at UC Health
3 in progress, 0 open to eligible people

  • An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

    Sorry, not accepting new patients

    The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.

    at UCLA

  • Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

    Sorry, not currently recruiting here

    Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref). The purpose of this study is to compare the efficacy safety and patient reported outcomes between oral octreotide capsules and injectable somatostatin analogs.

    at UCLA

  • Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

    Sorry, in progress, not accepting new patients

    Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below).

    at UCLA

Last updated: